^
    8d
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane
    10d
    Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • hydroxyurea • thiotepa • Neupogen (filgrastim) • Orencia (abatacept)
    11d
    A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma. (PubMed, Cancer Immunol Immunother)
    OH2 exerts antitumor activity in GBM through direct oncolysis and immune microenvironment modulation, highlighting its potential as an immunotherapeutic strategy.
    Journal
    |
    STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    BS001
    22d
    GPAD-3: Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (clinicaltrials.gov)
    P2, N=151, Completed, Emory University | Recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Leukine (sargramostim)
    23d
    Oncolytic vaccinia virus JX-594 shows subtype-specific activity and candidate biomarkers in gastric cancer cell lines. (PubMed, Sci Rep)
    Notably, JX-594 activity was not correlated with TK1 or EGFR expression, suggesting additional determinants of viral susceptibility in GC. These findings provide preclinical evidence that molecular heterogeneity influences the response of GC to oncolytic virotherapy and support further investigation of JX-594 as a potential therapeutic strategy for gastric cancer.
    Preclinical • Journal • MSi-H Biomarker
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability) • IL1A (Interleukin 1, alpha) • IL4I1 (Interleukin 4 Induced 1) • MX1 (MX Dynamin Like GTPase 1)
    |
    MSI-H/dMMR • EGFR expression
    |
    Pexa-Vec (pexastimogene devacirepvec)
    24d
    Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. (PubMed, J Surg Oncol)
    Intratumoral IT injection is a viable treatment option that may minimize systemic exposure while maintaining therapeutic efficacy. Breast surgeons can play a role in intratumoral IT in BC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Imlygic (talimogene laherparepvec) • Voyager-V1
    29d
    Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    Neupogen (filgrastim) • plerixafor
    29d
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=66, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> May 2028 | Trial primary completion date: Nov 2027 --> May 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor
    1m
    Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
    P1/2, N=22, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N=46 --> 22
    Enrollment change
    |
    Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
    1m
    A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=47, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Oct 2026 --> Jul 2026
    Enrollment open • Trial initiation date
    |
    CD4 (CD4 Molecule)
    |
    Inqovi (decitabine/cedazuridine) • Neupogen (filgrastim)
    1m
    Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors (clinicaltrials.gov)
    P2, N=132, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Neupogen (filgrastim)
    1m
    GRACE: GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study (clinicaltrials.gov)
    P4, N=75, Completed, Nationwide Children's Hospital | Active, not recruiting --> Completed | N=120 --> 75
    Trial completion • Enrollment change
    |
    Leukine (sargramostim)